Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2010

Open Access 01-02-2010 | Original Article

Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility

Authors: Marie Lipoldová, Helena Havelková, Jana Badalová, Jarmila Vojtíšková, Lei Quan, Magdaléna Krulová, Yahya Sohrabi, Alphons P. Stassen, Peter Demant

Published in: Cancer Immunology, Immunotherapy | Issue 2/2010

Login to get access

Abstract

Low infiltration of lymphocytes into cancers is associated with poor prognosis, but the reasons why some patients exhibit a low and others a high infiltration of tumors are unknown. Previously we mapped four loci (Lynf1–Lynf4) controlling lymphocyte infiltration of mouse lung tumors. These loci do not encode any of the molecules that are involved in traffic of lymphocytes. Here we report a genetic relationship between these loci and the control of production of IFNγ in allogeneic mixed lymphocyte cultures (MLC). We found that IFNγ production by lymphocytes of O20/A mice is lower than by lymphocytes of OcB-9/Dem mice (both H2 pz ) stimulated in MLC by irradiated splenocytes of C57BL/10SnPh (H2 b ) or BALB/cHeA (H2 d ) mice, or by ConA. IFNγ production in MLCs of individual (O20 × OcB-9)F2 mice stimulated by irradiated C57BL/10 splenocytes and genotyped for microsatellite markers revealed four IFNγ-controlling loci (Cypr4-Cypr7), each of which is closely linked with one of the four Lynf loci and with a cluster of susceptibility genes for different tumors. This suggests that inherited differences in certain lymphocyte responses may modify their propensity to infiltrate tumors and their capacity to affect tumor growth.
Literature
1.
de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37CrossRefPubMed
2.
Klein G, Imreh S, Zabarovsky ER (2007) Why do we not all die of cancer at an early age? Adv Cancer Res 98:1–16CrossRefPubMed
3.
Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50CrossRefPubMed
4.
Willimsky G, Blankenstein T (2007) The adaptive immune response to sporadic cancer. Immunol Rev 220:102–112CrossRefPubMed
5.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed
6.
Bui JD, Uppaluri R, Hsieh CS, Schreiber RD (2006) Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 66:7301–7309CrossRefPubMed
7.
Chen Q, Wang WC, Evans SS (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52:670–679CrossRefPubMed
8.
Horlings H, Demant P (2005) Lung tumor location and lymphocyte infiltration in mice are genetically determined. Exp Lung Res 31:513–525PubMedCrossRef
9.
Kakarlapudi N, Vernooy JH, Quan L, Fijneman RJ, Demant P (2008) Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci. Cancer Immunol Immunother 57:217–225CrossRefPubMed
10.
Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G (2004) Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. Cancer Res 64:3458–3464CrossRefPubMed
11.
Lipoldová M, Havelková H, Badalová J, Demant P (2005) Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility. Int J Cancer 114:394–399CrossRefPubMed
12.
Bodmer WF, Jones EA, Barnstable CJ, Bodmer JG (1978) Genetics HLA: the major human histocompatibility system. Proc R Soc Lond B Biol Sci 202:93–116CrossRefPubMed
13.
Huber BT (1992) Mls genes and self-superantigens. Trends Genet 8:399–402PubMed
14.
Feng X, Hui KM, Younes HM, Brickner AG (2008) Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 29:624–632CrossRefPubMed
15.
Rychlikova M, Demant P, Ivanyi P (1973) The mixed lymphocyte reaction in H-2K, H-2D, and non-H-2 incompatibility. Biomedicine 18:401–407PubMed
16.
Holán V, Havelková H, Krulová M, Demant P, Lipoldová M (2000) A novel alloreactivity-controlling locus, Alan1, mapped to mouse chromosome 17. Immunogenetics 51:755–757CrossRefPubMed
17.
Havelková H, Badalová J, Demant P, Lipoldová M (2000) A new type of genetic regulation of allogeneic response. A novel locus on mouse chromosome 4, Alan2 controls MLC reactivity to three different alloantigens: C57BL/10, BALB/c and CBA. Genes Immun 1:483–487CrossRefPubMed
18.
Demant P, Hart AA (1986) Recombinant congenic strains—a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 24:416–422CrossRefPubMed
19.
Holan V, Lipoldová M, Demant P (1996) Identical genetic control of MLC reactivity to different MHC incompatibilities, independent of production of and response to IL-2. Immunogenetics 44:27–35CrossRefPubMed
20.
Havelková H, Holan V, Karnik L, Lipoldová M (2006) Mouse model for analysis of non-MHC genes that influence allogeneic response: recombinant congenic strains of OcB/Dem series that carry identical H2 locus. Central European Journal of Biology 1:16–28CrossRef
21.
Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41–101CrossRefPubMed
22.
Street SE, Trapani JA, MacGregor D, Smyth MJ (2002) Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196:129–134CrossRefPubMed
23.
Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G (2003) Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 197:1213–1219CrossRefPubMed
24.
Qin Z, Kim HJ, Hemme J, Blankenstein T (2002) Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 195:1479–1490CrossRefPubMed
25.
Blankenstein T (2005) The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17:180–186CrossRefPubMed
26.
Klein J (1989) Immunologically important loci. In: Lyon M, Searle A (eds) Genetic variants and strains of the laboratory mouse. Oxford University Press, Oxford
27.
Stassen AP, Groot PC, Eppig JT, Demant P (1996) Genetic composition of the recombinant congenic strains. Mamm Genome 7:55–58CrossRefPubMed
28.
Lipoldová M, Kosarová M, Zajicová A, Holán V, Hart AA, Krulová M, Demant P (1995) Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains. Immunogenetics 41:301–311CrossRefPubMed
29.
Dietrich W, Katz H, Lincoln SE, Shin HS, Friedman J, Dracopoli NC, Lander ES (1992) A genetic map of the mouse suitable for typing intraspecific crosses. Genetics 131:423–447PubMed
30.
Tripodis N, Hart AA, Fijneman RJ, Demant P (2001) Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93:1484–1491CrossRefPubMed
31.
Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241–247CrossRefPubMed
32.
Kosarová M, Havelková H, Krulová M, Demant P, Lipoldová M (1999) The production of two Th2 cytokines, interleukin-4 and interleukin-10, is controlled independently by locus Cypr1 and by loci Cypr2 and Cypr3, respectively. Immunogenetics 49:134–141CrossRefPubMed
33.
Groot PC, Moen CJ, Dietrich W, Stoye JP, Lander ES, Demant P (1992) The recombinant congenic strains for analysis of multigenic traits: genetic composition. FASEB J 6:2826–2835PubMed
34.
Demant P (2003) Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. Nat Rev Genet 4:721–734CrossRefPubMed
35.
Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623–1626CrossRefPubMed
36.
Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE 2nd (1986) Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol 136:963–970PubMed
37.
Murata Y, Ohteki T, Koyasu S, Hamuro J (2002) IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol 32:2866–2873CrossRefPubMed
38.
Vilcek J, Henriksen-Destefano D, Siegel D, Klion A, Robb RJ, Le J (1985) Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2. J Immunol 135:1851–1856PubMed
39.
Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559–568CrossRefPubMed
40.
Kim KJ, Chaouat G, Leiserson WM, King J, De Maeyer E (1983) Characterization of T-cell-soluble factors modulating the expression of Ia and H-2 antigens on BALB/c B lymphoma cell lines. Cell Immunol 76:253–267CrossRefPubMed
41.
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556–7561CrossRefPubMed
42.
Nagase H, Mao JH, Balmain A (2003) Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 63:4849–4853PubMed
43.
Festing MF, Lin L, Devereux TR, Gao F, Yang A, Anna CH, White CM, Malkinson AM, You M (1998) At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J × BALB/c mice. Genomics 53:129–136CrossRefPubMed
44.
Wang H, Teske D, Tess A, Kohlhepp R, Choi Y, Kendziorski C, Moser AR (2007) Identification of novel modifier loci of Apc Min affecting mammary tumor development. Cancer Res 67:11226–11233CrossRefPubMed
45.
Lee GH, Bugni JM, Obata M, Nishimori H, Ogawa K, Drinkwater NR (1997) Genetic dissection of susceptibility to murine ovarian teratomas that originate from parthenogenetic oocytes. Cancer Res 57:590–593PubMed
46.
Tripodis N, Demant P (2003) Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry. Cancer Res 63:125–131
47.
Lee GH, Ogawa K, Nishimori H, Drinkwater NR (1995) Most liver epithelial cell lines from C3B6F1 mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4. Oncogene 11:2281–2287PubMed
48.
Cool M, Depault F, Jolicoeur P (2006) Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci. Genes Chromosomes Cancer 45:191–202CrossRefPubMed
49.
Meruelo D, Offer M, Flieger N (1981) Genetics of susceptibility for radiation-induced leukemia. Mapping of genes involved to chromosomes 1, 2, and 4, and implications for a viral etiology in the disease. J Exp Med 154:1201–1211CrossRefPubMed
50.
Santos J, Herranz M, Perez de Castro I, Pellicer A, Fernandez-Piqueras J (1998) A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4. Oncogene 17:925–929CrossRefPubMed
51.
Zhu XX, Kozarsky K, Strahler JR, Eckerskorn C, Lottspeich F, Melhem R, Lowe J, Fox DA, Hanash SM, Atweh GF (1989) Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species. J Biol Chem 264:14556–14560PubMed
52.
Cool M, Jolicoeur P (1999) Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res 59:2438–2444PubMed
53.
Fijneman RJ, Jansen RC, van der Valk MA, Demant P (1998) High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14. Cancer Res 58:4794–4798PubMed
54.
Fijneman RJ, Demant P (1995) A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4. Cancer Res 55:3179–3182PubMed
55.
Matsuda Y, Ozaki T, Enomoto H, Saito T, Sakiyama S (1996) Chromosome mapping of the mouse and rat homologs of the human DAN gene, D1S1733E. Mamm Genome 7:709–710CrossRefPubMed
56.
Mock BA, Krall MM, Dosik JK (1993) Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA 90:9499–9503CrossRefPubMed
57.
Dorward AM, Shultz KL, Horton LG, Li R, Churchill GA, Beamer WG (2005) Distal Chr 4 harbors a genetic locus (Gct1) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model. Cancer Res 65:1259–1264CrossRefPubMed
58.
Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA (2003) Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci USA 100:14982–14987CrossRefPubMed
59.
van Wezel T, Ruivenkamp CA, Stassen AP, Moen CJ, Demant P (1999) Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 59:4216–4218PubMed
60.
Bernichtein S, Petretto E, Jamieson S, Goel A, Aitman TJ, Mangion JM, Huhtaniemi IT (2008) Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology 149:651–661CrossRefPubMed
61.
Ko MS, Kitchen JR, Wang X, Threat TA, Wang X, Hasegawa A, Sun T, Grahovac MJ, Kargul GJ, Lim MK, Cui Y, Sano Y, Tanaka T, Liang Y, Mason S, Paonessa PD, Sauls AD, DePalma GE, Sharara R, Rowe LB, Eppig J, Morrell C, Doi H (2000) Large-scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development. Development 127:1737–1749PubMed
62.
Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC (2005) DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 579:1191–1196CrossRefPubMed
63.
Wang D, Lemon WJ, You M (2002) Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice. Oncogene 21:6858–6865CrossRefPubMed
Metadata
Title
Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility
Authors
Marie Lipoldová
Helena Havelková
Jana Badalová
Jarmila Vojtíšková
Lei Quan
Magdaléna Krulová
Yahya Sohrabi
Alphons P. Stassen
Peter Demant
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0739-y

Other articles of this Issue 2/2010

Cancer Immunology, Immunotherapy 2/2010 Go to the issue

Original Article

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

Original Article

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

Original Article

Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin

Original Article

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

Original Article

Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection

Erratum

Erratum to: Amyloid precursor-like protein 2 association with HLA class I molecules
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits